Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520450 | 0.93 | MEN1 (0.50) | KDM4EALDH1A1AOC3MEN1KMT2A | |
| SCHEMBL2483393 | 0.88 | AOC3 (0.48) | KDM4EALDH1A1AOC3MEN1KMT2A | |
| SCHEMBL2376819 | 0.80 | MAPT (0.60) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL12731646 | 0.79 | MEN1 (0.60) | ENPP2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL521556 | 0.79 | KMT2A (0.64) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL16934915 | 0.79 | MAPT (0.59) | ENPP2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL10127548 | 0.79 | BCL2A1 (0.55) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL24267643 | 0.77 | ALDH1A1 (0.57) | ALDH1A1KMT2AMAPTSLC6A9SLC6A5 | |
| SCHEMBL17630583 | 0.76 | MAPT (0.52) | ENPP2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL31398210 | 0.75 | MAPT (0.49) | KDM4EALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | ENPP2 399/4885KDM4E 192/4885ALDH1A1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.